SUBSCRIBE
SUBSCRIBE
News   Policy

Neurocrine Biosciences, Inc. Shares Fall On Drug Worries

April 26, 2006 | 
1 min read
Shares of Neurocrine Biosciences Inc. fell Tuesday despite reporting earnings that beat Wall Street's estimates, as analysts focused on Food and Drug Administration's looming decision on the company's insomnia treatment instead.
Regulatory
Pfizer
MORE ON THIS TOPIC
Contemporary art collage. Giang hand kicking office worker symbolizing dismissal. Unsuccessful employee. Job reduction. Concept of business, career, failure, success, troubles
Rare diseases
Ultragenyx Takes Second Hit as FDA Rejects Gene Therapy for Sanfilippo Syndrome
July 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Regulatory
FDA Mulls Speedier Reviews to Companies Willing To Lower Drug Costs
July 14, 2025
 · 
1 min read
 · 
Tristan Manalac
Contemporary art collage showing a hand giving a thumbs down surrounded by red arrows pointing down, concept of negative feedback and bad review
Complete response letters
Capricor Plunges on FDA Rejection of DMD Cell Therapy
July 11, 2025
 · 
3 min read
 · 
Tristan Manalac
Person buried in paperwork hand raised collage art. Man drown in work concept. Overwork illustration for news banner, web articles, and posters
FDA
FDA Rejections: We Read 200 CRLs So You Don’t Have To
July 11, 2025
 · 
5 min read
 · 
Annalee Armstrong